Coherus BioSciences Files Routine 8-K on Corporate Details
Ticker: CHRS · Form: 8-K · Filed: Jan 10, 2024 · CIK: 1512762
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, administrative, 8-K
TL;DR
**CHRS filed a standard 8-K, confirming basic company info; no new news.**
AI Summary
This 8-K filing from Coherus BioSciences, Inc. (CHRS) on January 10, 2024, is a routine administrative filing, specifically an "Other Events" report. It confirms the company's basic information, such as its Delaware incorporation, its business address at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065, and its common stock trading symbol 'CHRS' on The Nasdaq Global Market. This filing primarily serves to update or confirm corporate details, which is important for investors to ensure the company's public records are current and accurate, reflecting its operational and legal status.
Why It Matters
This filing confirms Coherus BioSciences' current corporate information, ensuring transparency and accuracy for investors tracking the company's public records and legal standing.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no new material information that would introduce significant risk.
Analyst Insight
Smart investors would note this as a routine administrative filing, confirming no new material developments. It's a good reminder to ensure their records align with the company's official details.
Key Numbers
- 001-36721 — Commission File Number (identifies the company's filings with the SEC)
- 27-3615821 — IRS Employer Identification Number (unique tax identification for the company)
- (650) 649-3530 — Registrant's telephone number (contact information for the company)
- $0.0001 — par value per share (nominal value of common stock)
Key Players & Entities
- Coherus BioSciences, Inc. (company) — registrant
- CHRS (company) — trading symbol
- The Nasdaq Global Market (company) — exchange where stock is registered
- Delaware (company) — state of incorporation
- 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 (dollar_amount) — principal executive offices address
- January 10, 2024 (dollar_amount) — date of report
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is COHERUS BIOSCIENCES, INC.
On what date was this 8-K report filed?
This 8-K report was filed on January 10, 2024, which is also the date of the earliest event reported.
What is the trading symbol for Coherus BioSciences, Inc. common stock and on which exchange is it registered?
The trading symbol for Coherus BioSciences, Inc. common stock is CHRS, and it is registered on The Nasdaq Global Market.
What is the principal executive office address for Coherus BioSciences, Inc.?
The principal executive office address for Coherus BioSciences, Inc. is 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.
What is the state or other jurisdiction of incorporation for Coherus BioSciences, Inc.?
Coherus BioSciences, Inc. is incorporated in Delaware.
Filing Stats: 578 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-01-09 21:39:46
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share CHRS The Nasdaq
Filing Documents
- chrs-20240110x8k.htm (8-K) — 35KB
- 0001558370-24-000165.txt ( ) — 159KB
- chrs-20240110.xsd (EX-101.SCH) — 4KB
- chrs-20240110_def.xml (EX-101.DEF) — 3KB
- chrs-20240110_lab.xml (EX-101.LAB) — 16KB
- chrs-20240110_pre.xml (EX-101.PRE) — 10KB
- chrs-20240110x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On January 10, 2024, Coherus BioSciences, Inc. (the "Company") announced that it had delivered a notice of termination of the TIGIT Program (as defined in the Collaboration Agreement) to Shanghai Junshi Biosciences, Co., Ltd ("Junshi Biosciences") pursuant to the Exclusive License and Commercialization Agreement (the "Collaboration Agreement") dated February 1, 2021, between the Company and Junshi Biosciences. The Company had previously notified Junshi Biosciences on January 9, 2022 of its election to exercise the license option for the TIGIT program CHS-006 described in the Collaboration Agreement (the "TIGIT Program"). After its acquisition of Surface Oncology, Inc. in September 2023, the Company disclosed that it would conduct a portfolio prioritization process to allocate resources towards the most promising and/or competitively positioned product candidates in its pipeline. The Company believes it is in its best interests to terminate future work with Junshi Biosciences on the TIGIT Program. The Company plans to wind down work with Junshi Biosciences on the TIGIT Program over the coming months pursuant to the termination. Despite the termination of the work with Junshi BioSciences on the TIGIT Program, the Company will continue to support patients in its current studies involving CHS-006 (clinicaltrials.gov identifier# NCT05061628 and clinicaltrials.gov identifier# NCT05757492). The Collaboration Agreement remains effective and active for all other purposes as the Company continues to work together with Junshi Biosciences on the development of LOQTORZI (toripalimab-tpzi).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 10, 2024 COHERUS BIOSCIENCES, INC. By: /s/ Dennis M. Lanfear Name: Dennis M. Lanfear Title: President and Chief Executive Officer